Related Experiment Video
Updated: Sep 27, 2025
The Influence of Liver Resection on Intrahepatic Tumor Growth
Published on: April 9, 2016
Retrospective Analysis of Pediatric Hepatoblastoma With Tumor Rupture: Experience From a Single Center
Yu-Tong Zhang1, Yu-Fei Zhao1, Dian-Fei Yang1
1Department of Pediatric Oncology, The First Hospital of Jilin University, Changchun, China.
Insights
Hepatoblastoma tumor rupture may not indicate a poor prognosis. Patients treated with peritoneal perfusion of interleukin-2 showed improved survival, suggesting this therapy plays a role in managing hepatoblastoma rupture.
Area of Science:
- Pediatric Oncology
- Surgical Oncology
- Hepatobiliary Malignancies
Background:
- Hepatoblastoma (HB) tumor rupture is often classified as a high-risk factor.
- Current risk stratification systems consider tumor rupture a significant prognostic indicator.
Purpose of the Study:
- To evaluate the predictive value of hepatoblastoma tumor rupture for patient prognosis.
- To determine if tumor rupture is an independent predictor of poor outcomes in hepatoblastoma.
Main Methods:
- Retrospective analysis of clinical data from children with high-risk HB or tumor rupture (2008-2017).
- Comparison of survival rates between high-risk HB group and tumor rupture group.
- Assessment of treatment response, including peritoneal perfusion with interleukin-2.
Main Results:
- The 3-year overall survival rate was significantly higher in the tumor rupture group (100%) compared to the high-risk group (64%, p=0.0427).
- Seven of nine patients (77.8%) in the tumor rupture group presented with hemoglobin levels ≤ 8 g/L at diagnosis.
- Seven of nine patients (77.8%) achieved complete response following treatment with peritoneal perfusion of interleukin-2; no deaths were reported at follow-up.
Conclusions:
- Hepatoblastoma tumor rupture may not be a predictor of poor prognosis.
- Peritoneal perfusion with interleukin-2 could be a crucial therapeutic strategy for managing hepatoblastoma rupture and preventing peritoneal dissemination/relapse.
Purpose:
Hepatoblastoma (HB) tumor rupture is currently considered as a high-risk factor in some risk stratification systems. This study aimed to investigate the value of HB tumor rupture in predicting the poor prognosis.
Methods:
The clinical data from children with high-risk HB or HB tumor rupture at our institution from October 2008 to 2017 were retrospectively reviewed and analyzed.
Results:
Together, 34 children with high-risk HB or HB tumor rupture were retrospected, including 25 in the high-risk group and nine in tumor rupture group. The 3-year overall survival (OS) rate in tumor rupture group was significantly higher than that of the high-risk group (100 vs. 64%, p = 0.0427). In tumor rupture group, seven (77.8%) of nine patients had a hemoglobin level ≤ 8 g/L and 3 of them (33.3%) had ≤ 6 g/L at the time of diagnosis. Peritoneal perfusion with interleukin-2 was implemented for each patient. At the end of the treatment, seven (77.8%) of nine patients achieved complete response (CR). No patient died at the last follow-up.
Conclusions:
HB tumor rupture might not be predictive of poor prognosis with the risk of peritoneal dissemination/relapse, in which peritoneal perfusion with interleukin-2 could play a role.
